Search for the latest oncology news by tumour type
NATALEE 4-year data: Ribociclib extends recurrence-free survival in early breast cancer
Hormone receptor (HR)–positive, ERBB2 (formerly HER2)–negative breast cancer is the most common subtype, accounting for…